Rockefeller Capital Management
DNLI icon

Rockefeller Capital Management’s Denali Therapeutics DNLI Stock Holding History

Rockefeller Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Sell
8,894
-17,041
-66% -$350K ﹤0.01% 2535
2026
Q1 		$498K Buy
25,935
+24,670
+1,950% +$491K ﹤0.01% 1978
2025
Q4 		$20.9K Buy
1,265
+182
+17% +$3.07K ﹤0.01% 3499
2025
Q3 		$15.7K Buy
+1,083
New +$15.6K ﹤0.01% 3457
2023
Q3 		– Sell
-8,888
Closed -$262K – 1565
2023
Q2 		$262K Buy
8,888
+164
+2% +$4.61K ﹤0.01% 1558
2023
Q1 		$200K Sell
8,724
-1,134
-12% -$31.2K ﹤0.01% 1816
2022
Q4 		$273K Sell
9,858
-1,976
-17% -$58.8K ﹤0.01% 1519
2022
Q3 		$362K Buy
11,834
+604
+5% +$19.6K ﹤0.01% 1391
2022
Q2 		$330K Sell
11,230
-8,422
-43% -$221K ﹤0.01% 1437
2022
Q1 		$631K Buy
19,652
+3,194
+19% +$110K ﹤0.01% 1228
2021
Q4 		$733K Buy
16,458
+1,659
+11% +$78.6K ﹤0.01% 1171
2021
Q3 		$745K Buy
14,799
+7,592
+105% +$428K ﹤0.01% 1106
2021
Q2 		$564K Buy
7,207
+2,817
+64% +$174K ﹤0.01% 1155
2021
Q1 		$249K Buy
4,390
+1,890
+76% +$127K ﹤0.01% 1265
2020
Q4 		$209K Hold
2,500
– – ﹤0.01% 1181
2020
Q3 		$89K Buy
+2,500
New +$75.3K ﹤0.01% 1298

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's DNLI Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Denali Therapeutics (DNLI) stake by 66% in Q2 2026, selling an estimated $350K and leaving 8,894 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Rockefeller Capital Management first reported a position in DNLI in Q3 2020 and has held it in 16 quarters since. The position peaked at $745K in Q3 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Rockefeller Capital Management held 8,894 shares of Denali Therapeutics worth $229K as of Q2 2026.
  • Rockefeller Capital Management sold 17,041 Denali Therapeutics shares in Q2 2026, an estimated $350K.
  • Denali Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2535 holding.
  • Rockefeller Capital Management first reported a position in Denali Therapeutics in Q3 2020 and has held it in 16 quarters since.
  • Rockefeller Capital Management's Denali Therapeutics position peaked at $745K in Q3 2021.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.